title: Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
abstract: BACKGROUND
  The prevalence of high-risk Human Papillomavirus DNA (hrHPV DNA) in women with negative Papanicolaou (Pap) test results provides a measure of residual risk for cervical neoplasia after cytology screening. The purpose of this study was to document the prevalence of hrHPV DNA in several thousand women ages > or =30 years with negative ThinPrep Imaging System (TIS)-imaged Pap test results in a large academic hospital cytology laboratory.
  
  
  METHODS
  All cytology-negative TIS-imaged ThinPrep Pap tests (TPPT) with hrHPV DNA tests that were performed by the United States Food and Drug Administration (FDA)-approved Hybrid Capture 2 (HC2) method from May 1, 2005 to November 20, 2006 were identified and reviewed. Imaged-negative Pap test slides associated with a positive hrHPV DNA test result were rescreened manually. Variation in hrHPV DNA prevalence was assessed for different age and ethnic groups.
  
  
  RESULTS
  Of 8070 imaged cytology-negative TPPT from women ages 11 to 90 years, hrHPV DNA test results were also available. Among 7426 women ages > or =30 years with a cytology-negative, TIS-imaged, Pap test, a significant age-associated decline in hrHPV DNA prevalence was noted, 3.4% in 3050 women ages 30-45 years, 2.4% in 7426 women ages 30-90 years, and 1.8% in 5491 women ages 40-90 years. The hrHPV DNA-positive rate was 2.3% in 6012 imaged cytology-negative white women and 4.1% in 739 imaged cytology-negative black women.
  
  
  CONCLUSIONS
  Very low HC2 hrHPV DNA rates in 7426 women ages > or =30 years with cytology-negative, TIS-imaged, ThinPrep, Pap tests were similar to recently published data from 1 other academic center and lower than rates reported in previous studies on cytology-negative North American or European women screened manually with conventional or liquid-based Pap tests. These data may impact assessments of how best to combine cytology and HPV testing.
authors: Department of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA. zhaoc@UPMC.edu
authors: Chengquan
authors: C
authors: Zhao
authors: Esther
authors: E
authors: Elishaev
authors: Ke-Hai
authors: KH
authors: Yuan
authors: Jing
authors: J
authors: Yu
authors: R Marshall
authors: RM
authors: Austin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002584:Cervix Uteri / Q000166:cytology / Q000821:virology*; D002648:Child; D004279:DNA, Viral / Q000032:analysis*; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000235:genetics*; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000821:virology*; D011230:Precancerous Conditions / Q000175:diagnosis / Q000821:virology*; D011237:Predictive Value of Tests; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000821:virology*; D014626:Vaginal Smears
chemical_list: D004279:DNA, Viral